Ana Anderson

Ana Anderson is an institute member of the Broad Institute, an associate professor of neurology at Harvard Medical School, a scientist at Brigham and Women’s Hospital, and a core faculty member of the Evergrande Center for Immunologic Diseases. She works in the field of cancer immunology, specifically on elucidating mechanisms of T cell regulation in tumor tissue. Her laboratory has contributed greatly to the understanding of how co-inhibitory molecules like Tim-3 and Tigit regulate T cell responses in cancer and has identified gene programs that underlie T cell states in tumor tissue.

Prior to working in the field of cancer immunology, Anderson studied autoimmunity. She is on the editorial board for OncoImmunology, Cellular Immunology, and Journal for Immunotherapy of Cancer. She served on the scientific advisory board for CoStim Pharmaceuticals, which Novartis acquired in 2014. Currently she serves on the scientific advisory boards for Potenza Therapeutics, Tizona Therapeutics, Compass Therapeutics, and Zumutor Biologics.

She obtained her B.S. summa cum laude in microbiology and immunology from the University of Miami and her Ph.D. in immunology from Harvard University.

Education

• Ph.D. Harvard University (1993 — 1999)
• BS University of Miami (1989 — 1993)

Companies

• Associate Professor of Neurology Harvard Medical School (2017)
• Assistant Professor of Neurology Harvard Medical School (2010 — 2017)
• Instructor in Neurology Harvard Medical School (2005 — 2010)